cannabidiol/tetramethylpyrazine cocrystal (ART12.11) / Artelo Biosci - LARVOL DELTA

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results (GlobeNewswire) - "ART26.12: Phase I study is on track for completion in Q2 2025. ART27.13: Initial data from the Phase 2 CAReS trial anticipated by the end of Q2 2025. ART12.11: Substantial progress has been made toward initiation of human studies with an oral solid dosage form in 2H 2025."

New trial • P2 data • Trial completion date • Anorexia • CNS Disorders • Pain

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex (GlobeNewswire) - "Artelo Biosciences, Inc...today announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). The findings were presented by Professor Saoirse O’Sullivan, Vice President of Translational Science at Artelo Biosciences, at the International Medical Cannabis Conference (IMCCB-25), held February 13-14, 2025, at the University of Bern, Switzerland...The studies showed that two different tablet formulations of ART12.11 achieved CBD and metabolite exposure levels similar or greater to the equivalent dose of Epidiolex, supporting the potential of ART12.11 as an alternative formulation of CBD."

Preclinical • CNS Disorders

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland (GlobeNewswire) - "Artelo Biosciences...announced that it will be presenting data on ART12.11, a proprietary cocrystal composed of cannabidiol (CBD) and tetramethylpyrazine (TMP), at the International Medical Cannabis Conference (IMCCB-25) held at the University of Bern, Switzerland February 13-14, 2025....The presentation will showcase Artelo’s recently obtained pharmacokinetic results in canine studies with the Company’s proprietary oral solid compositions of ART12.11 compared to Epidiolex."

Preclinical • Depression

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany (GlobeNewswire) - "Artelo Biosciences, Inc...announced new preclinical data on ART12.11, the Company’s proprietary cocrystal of cannabidiol (CBD) and tetramethylpyrazine (TMP), was presented at the 4th Annual Med-Cannabis 2023 conference today, December 5, 2023 in Frankfurt, Germany....The presentation included results from additional preclinical studies that demonstrated greater anxiolytic, anti-depressive, and pro-social effects of ART12.11 compared to CBD alone."

Preclinical • CNS Disorders • Major Depressive Disorder • Mood Disorders

Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany (GlobeNewswire) - "Artelo Biosciences, Inc...today announced George Warren, PhD., Principal Scientist at Artelo Biosciences, will be presenting new preclinical data on ART12.11, the Company’s proprietary cocrystal of cannabidiol (CBD) and tetremethylpyrazine (TMP), at the 4th Annual Med-Cannabis 2023 conference being held December 4-5, 2023 in Frankfurt, Germany."

Preclinical • CNS Disorders

A novel cannabidiol:tetramethylpyrazine (CBD:TMP) cocrystal improves the efficacy and bioavailability of cannabidiol to induce anxiolytic and anti-depressant effects (Neuroscience 2023) - "Altogether, these results suggest the cocrystal CBD:TMP improves the efficacy and bioavailability of CBD. Overall, this research supports the development of CBD:TMP as a promising and superior alternative to CBD in the pharmacotherapeutic treatment of anxiety and depressive symptoms and phenotypes."

Clinical • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry

Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire) - "Artelo Biosciences, Inc...presented important new data from multiple preclinical studies regarding ART12.11, Artelo’s patented cannabidiol (CBD) cocrystal, on Sunday, June 25th, at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada...'ART12.11, which demonstrate improved bioavailability and efficacy in nonclinical models of stress-induced anxiety versus CBD.'...'As a follow up to an initial single dose study with ART12.11, a multiple dose pharmacokinetic animal study conducted at different research laboratories, showed that this novel cocrystal form of CBD demonstrated improved pharmaceutical properties, including solubility and dissolution, and delivered higher plasma levels of CBD and its major metabolite compared to CBD alone...'"

Preclinical • CNS Disorders • Post-traumatic Stress Disorder

Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire) - "Artelo Biosciences, Inc...announced that it was selected for an oral presentation at the 33rd International Cannabinoid Research Society (ICRS) Symposium being held on June 24-29, 2023 in Toronto, Ontario, Canada, at the Marriott Downtown at CF Toronto Eaton Centre....Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, is scheduled to present new data on ART12.11, Artelo’s patented cannabidiol cocrystal, at the ICRS on Sunday, June 25th at 9:15 EDT. Results from preclinical studies with ART12.11 in stress-induced anxiety and depression that were conducted at the laboratory of Professor Steven Laviolette at the University of Western Ontario, Canada, will be presented by Professor O’Sullivan as well as data related to ART12.11’s pharmacokinetics as compared to other forms of CBD."

Clinical data • Preclinical • CNS Disorders • Depression

Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update (Yahoo Finance) - "...'we continue to advance both our ART26.12 cancer program and ART12.11, our patented cocrystal of cannabidiol (CBD). With cash on hand expected to support operations into the second half of 2023, we expect to reach meaningful clinical and developmental milestones, namely, the complete data readout from our CAReS study, as well as the progress of preclinical research supporting the initiation of human trials for both ART26.12 and ART12.11.'"

Commercial • Inflammatory Bowel Disease

Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol (GlobeNewswire) - "Artelo Biosciences, Inc...announced that the Company received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/835,383 entitled 'Solid Forms of Cannabidiol and Uses Thereof' related to its ART12.11 program, a cocrystal composition of cannabidiol (CBD). In addition, the Company has pending foreign patent applications covering cocrystal composition-of-matter and method of use."

Patent • Inflammatory Bowel Disease

The Pharmacological Effects of Plant-Derived versus Synthetic Cannabidiol in Human Cell Lines. (PubMed, Med Cannabis Cannabinoids) - "Our results suggest that there is no pharmacological difference in vitro in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD. The purity and reliability of CBD samples, as well as the ultimate pharmaceutical preparation, should all be considered above the starting source of CBD in the development of new CBD medicines."

Journal • Preclinical • Cardiovascular • Immunology • Inflammation • Oncology • Ovarian Cancer • Solid Tumor • IFNG • IL6 • TNFA

Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire) - "ART12.11 is a patented cocrystal of cannabidiol (CBD) and tetramethylpyrazine (TMP), which may have the potential to prevent cancer cell growth and kill cancer cells. The Company also continues to generate data on its FABP5 inhibitor, ART26.12, as a potential anti-cancer treatment, supported by FABP5's emerging utility as a biomarker...Presented a poster at ICRS related to Artelo’s ART12.11 CBD Cocrystal and the potential to prevent cancer cell growth and kill cancer cells through co-administration of CBD and TMP."

Clinical • Preclinical • Oncology

Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire) - "Second Quarter Fiscal 2021 Highlights: Announced positive laboratory data associated with proprietary CBD cocrystal demonstrating co-administration of CBD and TMP could confer ART12.11 with a more desirable pharmacodynamic profile."

Preclinical • Inflammatory Bowel Disease

Artelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update (GlobeNewswire) - "Notably, Artelo was awarded the first and only composition of matter patent for our novel cocrystal of CBD, ART12.11, establishing a basis for market exclusivity through the end of 2038 and supporting our development for PTSD and inflammatory bowel disease."

Patent • Inflammatory Bowel Disease

Artelo Biosciences awarded composition of matter patent for novel CBD cocrystal (GlobeNewswire, Artelo Biosciences) - "Artelo Biosciences, Inc....today announced that the U.S. Patent and Trademark Office has issued a 'composition of matter' patent with claims covering ART12.11, the company’s cocrystal, solid form of CBD (cannabidiol) and TMP (tetramethypyrazine). The new U.S. patent, No. 10,604467 for 'Solid Forms of Cannabidiol and Uses Thereof,' provides intellectual property protection for ART12.11 until December 10, 2038."

Patent • Immunology • Inflammatory Bowel Disease

Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update (GlobeNewswire, Artelo Biosciences) - "For our lead clinical program ART27.13, manufacturing and regulatory approvals are proceeding as planned for the initiation of our Phase 1b/2a clinical study for the treatment of cancer-related anorexia. In addition, we reinforced our intellectual property position for ART12.11 and are closing in on the identification of the lead candidate for ART26.12, our fatty acid binding protein 5 (FABP5) inhibitor program for the potential treatment of various cancers, pain and inflammation. 'Despite the impact of the COVID-19 pandemic, Artelo remains well positioned to achieve a number of meaningful milestones in 2020, including initiating enrollment in our Phase 1b/2a clinical study of ART27.13, reporting key pre-clinical data related to ART12.11 and ART26.12, as well as advancing discussions with potential development partners,' added Mr."

Commercial • Enrollment status • New trial • Preclinical • Anorexia • CNS Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Novel Coronavirus Disease • Oncology • Pain • Psychiatry